J M Kremer

Summary

Affiliation: Center for Rheumatology
Country: USA

Publications

  1. pmc Malignancy validation in a United States registry of rheumatoid arthritis patients
    Mark C Fisher
    Massachusetts General Hospital, 55 Fruit St, Boston, MA 02114, USA
    BMC Musculoskelet Disord 13:85. 2012
  2. pmc Integrated safety in tocilizumab clinical trials
    Michael H Schiff
    Rheumatology Division, University of Colorado School of Medicine, 5400 South Monaco Street, Greenwood Village, CO 80111, USA
    Arthritis Res Ther 13:R141. 2011
  3. doi request reprint A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone
    Joel M Kremer
    Albany Medical College, Albany, New York 12206, USA
    Arthritis Rheum 64:970-81. 2012
  4. ncbi request reprint Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial
    Joel M Kremer
    Center for Rheumatology, Albany, NY 12206, USA
    Arthritis Rheum 52:2263-71. 2005
  5. pmc The CORRONA database
    J Kremer
    Center for Rheumatology, Albany Medical College, 1367 Washington Avenue, Albany, NY 12203, USA
    Ann Rheum Dis 64:iv37-41. 2005
  6. doi request reprint Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structu
    Joel M Kremer
    Albany Medical College and Center for Rheumatology, Albany, New York 12206, USA
    Arthritis Rheum 63:609-21. 2011
  7. ncbi request reprint The CORRONA database
    Joel M Kremer
    Albany Medical College, The Center for Rheumatology, Albany, New York 12203, USA
    Autoimmun Rev 5:46-54. 2006
  8. ncbi request reprint Selective costimulation modulators: a novel approach for the treatment of rheumatoid arthritis
    Joel M Kremer
    Department of Medicine and Research, The Center for Rheumatology, Albany Medical College, 1367 Washington Avenue, Albany, NY 12206, USA
    J Clin Rheumatol 11:S55-62. 2005
  9. pmc Methotrexate pharmacogenomics
    J M Kremer
    Center for Rheumatology, Albany Medical College, Albany, NY 12206, USA
    Ann Rheum Dis 65:1121-3. 2006
  10. ncbi request reprint Rheumatoid arthritis: a rapidly evolving treatment paradigm
    Joel M Kremer
    The Center for Rheumatology, Albany Medical College, New York 12203, USA
    Manag Care Interface 20:17, 24. 2007

Detail Information

Publications44

  1. pmc Malignancy validation in a United States registry of rheumatoid arthritis patients
    Mark C Fisher
    Massachusetts General Hospital, 55 Fruit St, Boston, MA 02114, USA
    BMC Musculoskelet Disord 13:85. 2012
    ..However, little is known on the accuracy of physician reported malignancies compared to pertinent medical record review in large cohort studies...
  2. pmc Integrated safety in tocilizumab clinical trials
    Michael H Schiff
    Rheumatology Division, University of Colorado School of Medicine, 5400 South Monaco Street, Greenwood Village, CO 80111, USA
    Arthritis Res Ther 13:R141. 2011
    ..Patients from these randomized trials could receive tocilizumab treatment in open-label extension trials. Here, the long-term safety profile of tocilizumab, using pooled data from all of these trials, is reported...
  3. doi request reprint A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone
    Joel M Kremer
    Albany Medical College, Albany, New York 12206, USA
    Arthritis Rheum 64:970-81. 2012
    ....
  4. ncbi request reprint Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial
    Joel M Kremer
    Center for Rheumatology, Albany, NY 12206, USA
    Arthritis Rheum 52:2263-71. 2005
    ..To determine the clinical efficacy, safety, and immunogenicity of abatacept (CTLA-4Ig), a selective costimulation modulator, in patients with rheumatoid arthritis (RA) that has remained active despite methotrexate (MTX) therapy...
  5. pmc The CORRONA database
    J Kremer
    Center for Rheumatology, Albany Medical College, 1367 Washington Avenue, Albany, NY 12203, USA
    Ann Rheum Dis 64:iv37-41. 2005
  6. doi request reprint Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structu
    Joel M Kremer
    Albany Medical College and Center for Rheumatology, Albany, New York 12206, USA
    Arthritis Rheum 63:609-21. 2011
    ....
  7. ncbi request reprint The CORRONA database
    Joel M Kremer
    Albany Medical College, The Center for Rheumatology, Albany, New York 12203, USA
    Autoimmun Rev 5:46-54. 2006
    ..These databases can provide data which is well beyond what is available from industry-sponsored investigations...
  8. ncbi request reprint Selective costimulation modulators: a novel approach for the treatment of rheumatoid arthritis
    Joel M Kremer
    Department of Medicine and Research, The Center for Rheumatology, Albany Medical College, 1367 Washington Avenue, Albany, NY 12206, USA
    J Clin Rheumatol 11:S55-62. 2005
    ..This clinical experience indicates that abatacept is a significant addition to the therapeutic armamentarium for the management of patients with RA...
  9. pmc Methotrexate pharmacogenomics
    J M Kremer
    Center for Rheumatology, Albany Medical College, Albany, NY 12206, USA
    Ann Rheum Dis 65:1121-3. 2006
  10. ncbi request reprint Rheumatoid arthritis: a rapidly evolving treatment paradigm
    Joel M Kremer
    The Center for Rheumatology, Albany Medical College, New York 12203, USA
    Manag Care Interface 20:17, 24. 2007
  11. doi request reprint The role of drug and disease registries in rheumatic disease epidemiology
    Joel M Kremer
    Albany Medical College, 1367 Washington Avenue, Albany, NY 12206, USA
    Curr Opin Rheumatol 20:123-30. 2008
    ..This review highlights the present state of efforts at registry implementation which exist internationally. These efforts are contrasted with those in the USA...
  12. doi request reprint Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate
    Joel M Kremer
    Center for Rheumatology, Albany Medical College, Albany, New York 12206, USA
    Arthritis Rheum 58:953-63. 2008
    ..To evaluate the efficacy, radiographic changes, and safety of abatacept and methotrexate therapy through 2 years in a long-term extension of a previously published 1-year study...
  13. doi request reprint COMET's path, and the new biologicals in rheumatoid arthritis
    Joel M Kremer
    Center for Rheumatology, Albany Medical College, Albany, NY 12206, USA
    Lancet 372:347-8. 2008
  14. doi request reprint Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study
    Joel Kremer
    Albany Medical College and The Center for Rheumatology, Albany, New York 12206, USA
    Arthritis Rheum 62:917-28. 2010
    ..To assess the efficacy and safety of intravenous administration of golimumab in patients with rheumatoid arthritis (RA)...
  15. pmc Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial
    Joel M Kremer
    Center for Rheumatology, Albany Medical College, 1367 Washington Ave, Albany, NY 12206, USA
    Ann Rheum Dis 70:1826-30. 2011
    ..To evaluate abatacept treatment over 3 years in patients with rheumatoid arthritis (RA) refractory to methotrexate (MTX)...
  16. ncbi request reprint Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial
    Joel M Kremer
    Center for Rheumatology, Albany, New York, USA
    Ann Intern Med 144:865-76. 2006
    ..The selective co-stimulation modulator abatacept demonstrated efficacy for treating rheumatoid arthritis in early clinical studies...
  17. ncbi request reprint Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trial
    Joel Kremer
    Center for Rheumatology, Albany, New York 12206, USA
    J Rheumatol 31:1521-31. 2004
    ..To obtain additional safety and efficacy data on leflunomide (LEF) treatment in combination with methotrexate (MTX) therapy in an open-label extension study in patients with rheumatoid arthritis (RA)...
  18. ncbi request reprint New and emerging therapies for rheumatoid arthritis
    Joel M Kremer
    The Center for Rheumatology, 1367 Washington Avenue, Albany, NY 12203, USA
    Rheum Dis Clin North Am 30:xi-xii. 2004
  19. ncbi request reprint Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations
    Joel M Kremer
    The Center for Rheumatology, Albany, New York 12206, USA
    Arthritis Rheum 48:1493-9. 2003
    ....
  20. ncbi request reprint Tacrolimus in rheumatoid arthritis patients receiving concomitant methotrexate: a six-month, open-label study
    Joel M Kremer
    Center for Rheumatology, Albany, New York 12206, USA
    Arthritis Rheum 48:2763-8. 2003
    ..To assess the safety of tacrolimus used in combination with oral methotrexate (MTX) to control the signs and symptoms of rheumatoid arthritis (RA) in patients whose disease remains active despite treatment with MTX...
  21. ncbi request reprint Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig
    Joel M Kremer
    Center for Rheumatology, Albany, NY 12206, USA
    N Engl J Med 349:1907-15. 2003
    ..CTLA4Ig binds to CD80 and CD86 on antigen-presenting cells, blocking the engagement of CD28 on T cells and preventing T-cell activation. A preliminary study showed that CTLA4Ig may be effective for the treatment of rheumatoid arthritis...
  22. ncbi request reprint Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial
    Joel M Kremer
    The Center for Rheumatology, LLP, 1367 Washington Avenue, Suite 101, Albany, NY 12206, USA
    Ann Intern Med 137:726-33. 2002
    ..Disease-modifying antirheumatic drugs may confer greater benefits when combined with the antimetabolite methotrexate...
  23. ncbi request reprint Toward a better understanding of methotrexate
    Joel M Kremer
    Albany Medical College, and The Center for Rheumatology, 1367 Washington Avenue, Albany, New York, USA
    Arthritis Rheum 50:1370-82. 2004
  24. ncbi request reprint Cytotoxic T-lymphocyte antigen 4-immunoglobulin in rheumatoid arthritis
    Joel M Kremer
    The Center for Rheumatology, 1367 Washington Avenue, Albany, NY 12203, USA
    Rheum Dis Clin North Am 30:381-91, viii. 2004
    ....
  25. ncbi request reprint Rational use of new and existing disease-modifying agents in rheumatoid arthritis
    J M Kremer
    The Center for Rheumatology, Albany, New York, USA
    Ann Intern Med 134:695-706. 2001
    ..This will allow the value of aggressive treatment to be established with certainty...
  26. pmc Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry
    J D Greenberg
    New York University Hospital for Joint Diseases, New York, USA
    Ann Rheum Dis 69:380-6. 2010
    ..To examine the association of methotrexate (MTX) and tumour necrosis factor (TNF) antagonists with the risk of infectious outcomes including opportunistic infections in patients with rheumatoid arthritis (RA)...
  27. ncbi request reprint Greater remission rates in patients with early versus long-standing disease in biologic-naive rheumatoid arthritis patients treated with abatacept: a post hoc analysis of randomized clinical trial data
    Y Yazici
    NYU University Hospital for Joint Diseases, New York, NY, USA
    Clin Exp Rheumatol 29:494-9. 2011
    ....
  28. ncbi request reprint The CORRONA database
    J M Kremer
    Albany Medical College, The Center for Rheumatology, Albany, New York 12203, USA
    Clin Exp Rheumatol 23:S172-7. 2005
    ..These databases can provide data which is well beyond what is available from industry-sponsored investigations...
  29. ncbi request reprint Benefit/risk of leflunomide in rheumatoid arthritis
    J M Kremer
    The Center for Rheumatology, Clinical Professor of Medicine, Albany Medical College, Albany, New York 12206, USA
    Clin Exp Rheumatol 22:S95-100. 2004
    ..Based on its success as an immunosuppressive agent in these models, leflunomide was tested for the treatment of rheumatoid arthritis (RA)...
  30. ncbi request reprint The COX-2 inhibitor market withdrawals and prescribing patterns by rheumatologists in patients with gastrointestinal and cardiovascular risk
    J D Greenberg
    New York University Hospital for Joint Diseases, New York, NY 10003, USA
    Clin Exp Rheumatol 27:395-401. 2009
    ..To examine effects of the COX-2 inhibitor market withdrawals on NSAID utilization among patients at increased risk of gastrointestinal (GI) and cardiovascular (CV) toxicities...
  31. ncbi request reprint Potential of tumor necrosis factor neutralization strategies in rheumatologic disorders other than rheumatoid arthritis
    David G Stokes
    Department of Medicine, Thomas Jefferson University, Philadelphia, PA, USA
    Semin Arthritis Rheum 33:1-18. 2003
    ..To consider the potential of tumor necrosis factor (TNF) neutralization in rheumatologic disorders other than rheumatoid arthritis (RA)...
  32. ncbi request reprint What I would like to know about leflunomide
    Joel M Kremer
    J Rheumatol 31:1029-31. 2004
  33. ncbi request reprint Use of combination of leflunomide with biological agents in treatment of rheumatoid arthritis
    Joachim R Kalden
    Medizinische Klinik III, Institute for Clinical Immunology, Erlangen, Germany
    J Rheumatol 32:1620-31. 2005
    ....
  34. pmc Tumor necrosis factor antagonist responsiveness in a United States rheumatoid arthritis cohort
    Jeffrey D Greenberg
    New York University Hospital for Joint Diseases, New York, NY 10003, USA
    Am J Med 121:532-8. 2008
    ..The study objective was to investigate responsiveness according to whether patients satisfy eligibility criteria from randomized controlled trials of tumor necrosis factor (TNF) antagonists in a multicentered US cohort...
  35. ncbi request reprint Treatment of rheumatoid arthritis with etanercept
    Mark C Genovese
    Division of Immunology and Rheumatology, Stanford University Medical Center, 1000 Welch Road, Suite 203, Palo Alto, CA 94304, USA
    Rheum Dis Clin North Am 30:311-28, vi-vii. 2004
    ..In addition to its use in RA,etanercept is approved by the U.S. Food and Drug Administration for other rheumatologic conditions, including psoriatic arthritis,ankylosing spondylitis, and juvenile chronic arthritis...
  36. ncbi request reprint Not yet time to change the guidelines for monitoring methotrexate liver toxicity: they have served us well
    Joel M Kremer
    J Rheumatol 29:1590-2. 2002
  37. ncbi request reprint Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial
    Edward C Keystone
    Mt Sinai Hospital, Toronto, Ontario, Canada
    Arthritis Rheum 50:353-63. 2004
    ..To evaluate the safety, efficacy, and pharmacokinetics of 50 mg etanercept administered subcutaneously once weekly in adult patients with active rheumatoid arthritis (RA)...
  38. ncbi request reprint Leflunomide
    Grant W Cannon
    Division of Rheumatology, Department of Medicine, University of Utah, 30 North 1900 East, Salt Lake City, UT 84132, USA
    Rheum Dis Clin North Am 30:295-309, vi. 2004
    ..Close monitoring for adverse events with particular attention for monitoring liver enzymes for hepatic toxicity is important during treatment with leflunomide...
  39. ncbi request reprint Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience
    Larry W Moreland
    Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL 35294 7201, USA
    J Rheumatol 33:854-61. 2006
    ..To evaluate safety and efficacy of longterm etanercept treatment in patients with disease modifying antirheumatic drug (DMARD) refractory rheumatoid arthritis (RA)...
  40. ncbi request reprint Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis
    Michael H Weisman
    Cedars Sinai Medical Center, Los Angeles, California, USA
    Arthritis Rheum 54:607-12. 2006
    ..This study investigated whether risk genotypes for folate-dependent enzymes are associated with the toxicity of MTX in patients with rheumatoid arthritis (RA)...
  41. ncbi request reprint Rheumatological creativity and leflunomide
    Joel M Kremer
    J Rheumatol 31:203-4. 2004
  42. ncbi request reprint CANDOO and CANOAR, CORRONA and more: advancing therapeutics through layered-in clinical data collection and feedback at the point of care
    Rolf J Sebaldt
    J Rheumatol 30:2308-11. 2003
  43. ncbi request reprint Radiographic benefit without clinical improvement in infliximab-treated patients with rheumatoid arthritis: comment on the article by Smolen et al
    Theodore Pincus
    Arthritis Rheum 52:4044-5; author reply 4045-7. 2005
  44. doi request reprint American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis
    Kenneth G Saag
    University of Alabama, Birmingham, AL, USA
    Arthritis Rheum 59:762-84. 2008